Clinical and virological characteristics post HBsAg seroclearance in hepatitis B virus carriers with hepatic steatosis versus those without

Digestive Diseases and Sciences

Volumn 58, Issue 1, 2013, Pages 275-281

  Chu, Chia Ming ^a   Lin, Deng Yn ^a   Liaw, Yun Fan ^a  

^a CHANG GUNG UNIVERSITY   (Taiwan)

Author keywords

Body mass index, BMI; HBsAg carriers; HBsAg seroclearance; HBV viremia; Hepatic steatosis; Liver cirrhosis

Indexed keywords

ALANINE AMINOTRANSFERASE; ASPARTATE AMINOTRANSFERASE; HEPATITIS B SURFACE ANTIBODY; HEPATITIS B SURFACE ANTIGEN;

ADULT; AGE; ALANINE AMINOTRANSFERASE BLOOD LEVEL; ARTICLE; ASPARTATE AMINOTRANSFERASE BLOOD LEVEL; BODY MASS; COMPARATIVE STUDY; CONTROLLED STUDY; DISEASE ASSOCIATION; DISEASE COURSE; ECHOGRAPHY; FATTY LIVER; FEMALE; FOLLOW UP; HEPATITIS B; HEPATITIS B VIRUS; HUMAN; LIVER CELL CARCINOMA; LIVER CIRRHOSIS; LIVER FIBROSIS; MAJOR CLINICAL STUDY; MALE; PRIORITY JOURNAL; SEROCONVERSION; VIREMIA; VIRUS CARRIER;

ADULT; AGED; FATTY LIVER; FEMALE; HEPATITIS B SURFACE ANTIGENS; HEPATITIS B VIRUS; HEPATITIS B, CHRONIC; HUMANS; LIVER CIRRHOSIS; MALE; MIDDLE AGED; TAIWAN;

EID: 84873183024     PISSN: 01632116     EISSN: 15732568     Source Type: Journal    
DOI: 10.1007/s10620-012-2343-9     Document Type: Article

References (34)

1. Liaw YF, Chu CM. Hepatitis B virus infection. Lancet. 2009;373:582-592.
2. Hsu YS, Chien RN, Yeh CT, et al. Long-term outcome after spontaneous HBeAg seroconversion in patients with chronic hepatitis B. Hepatology. 2002;35:1522-1527.
3. Chu CM, Hung SJ, Lin J, Tai DI, Liaw YF. Natural history of hepatitis be antigen to antibody seroconversion in patients with normal serum aminotransferase levels. Am J Med. 2004;116:829-834.
4. Liaw YF, Sheen IS, Chen TJ, Chu CM, Pao CC. Incidence, determinants and significance of delayed clearance of serum HBsAg in chronic hepatitis B virus infection: a prospective study. Hepatology. 1991;13:627-631.
5. Chu CM, Liaw YF. HBsAg seroclearance in asymptomatic carriers of high endemic areas: appreciably high rates during a long-term follow-up. Hepatology. 2007;45:1187-1192.
6. Chu CM, Liaw YF. Hepatitis B surface antigen seroclearance during chronic HBV infection. Antivir Ther. 2010;15:133-143.
7. Chu CM, Lin DY, Liaw YF. Does increased body mass index with hepatic steatosis contribute to seroclearance of hepatitis B virus (HBV) surface antigen in chronic HBV infection? Int J Obes (Lond). 2007;31:871-875.
8. Liu J, Yang HI, Lee MH, et al. Incidence and determinants of spontaneous Hepatitis B surface antigen seroclearance: a community-based follow-up study. Gastroenterology. 2010;139:474-482.
9. Machado MV, Oliveira AG, Cortez-Pinto H. Hepatic steatosis in hepatitis B virus infected patients: meta-analysis of risk factors and comparison with hepatitis C infected patients. J Gastroenterol Hepatol. 2011;26:1361-1367.
10. Chen YC, Sheen IS, Chu CM, Liaw YF. Prognosis following spontaneous HBsAg seroclearance in chronic hepatitis B patients with or without concurrent infection. Gastroenterology. 2002;123:1084-1089.
11. Ratziu V, Poynard T. NASH: a hidden and silent fibroser finally revealed. J Hepatol. 2005;42:132-138.
12. Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF. Clinical significance of ultrasonographical fatty live in asymptomatics: analysis of 1040 check-up subjects. J Med Ultrasound. 1993;1:165-171.
13. Saverymittu SH, Joseph AEA, Maewell MD. Ultrasound scanning in the detection of hepatic fibrosis and steatosis. BMJ. 1986;292:13-15.
14. Lin DY, Sheen IS, Chiu CT, Lin SM, Kuo YC, Liaw YF. Ultrasonographic changes of early liver cirrhosis in chronic hepatitis B: a longitudinal study. J Clin Ultrasound. 1993;21:303-308.
15. Hochberger S, Althof D, de Schrott G, Nachbaur N, Rock H, Leying H. Fully automated quantitation of hepatitis B virus (HBV) DNA in human plasma by the COBAS AmpliPrep/COBAS TaqMan System. J Clin Virol. 2006;35:373-380.
16. Chu CM, Liaw YF, Sheen IS, Kin DY, Huang MJ. Sex difference in chronic hepatitis B virus infection: an appraisal based on the status of hepatitis B e antigen and antibody. Hepatology. 1983;3:947-950.
17. Chu CM, Sheen IS, Lin SM, Liaw YF. Sex difference in chronic hepatitis B virus infection: studies of serum HBeAg and alanine aminotransferase levels in 10,431 asymptomatic Chinese HBsAg carriers. Clin Infect Dis. 1993;16:709-713.
18. Hwang LC, Bai CH, Chen CJ. Prevalence of obesity and metabolic syndrome in Taiwan. J Formos Med Assoc. 2006;105:626-635.
19. Huang KC. Obesity and its related diseases in Taiwan. Obes Rev. 2008;9:32-34.
20. Lin YC, Chou SC, Huang PT, Chiou HY. Risk factors and predictors of non-alcoholic fatty liver disease in Taiwan. Ann Hepatol. 2011;10:125-132.
21. Shlomai A, Shaul Y. The "metabolovirus" model of hepatitis B virus nutritional therapy as an effective anti-viral weapon. Med Hypothesis. 2008;71:53-57.
22. Bar-Yishay I, Shaul Y, Shlomai A. Hepatocyte metabolic signaling pathways and regulation of hepatitis B virus expression. Liver Int. 2011;31:285-290.
23. Pettinelli P, Del Pozo T, Araya J, et al. Enhancement in liver SREBP-1c/PPAR-alpha ratio and steatosis in obese patients: correlations with insulin resistance and n-3 long-chain polyunsaturated fatty acid depletion. Biochim Biophys Acta. 2009;1792:1080-1086.
24. Furusyo N, Hayashi J, Sawayama Y, Kishihara Y, Kashiwagi S. Hepatitis B surface antigen disappearance and hepatitis B surface antigen subtype: a prospective, long-term, follow-up study of Japanese residents of Okinawa, Japan with chronic hepatitis B virus infection. Am J Trop Med Hyg. 1999;60:616-622.
25. Manno M, Cammà C, Schepis F, et al. Natural history of chronic HBV carriers in northern Italy: morbidity and mortality after 30 years. Gastroenterology. 2004;127:756-763.
26. Ahn SH, Park YN, Park JY, Chang HY, et al. Long-term clinical and histological outcomes in patients with spontaneous hepatitis B surface antigen seroclearance. J Hepatol. 2005;42:188-194.
27. Yuen MF, Wong DK, Fung J, et al. HBsAg Seroclearance in chronic hepatitis B in Asian patients: replicative level and risk of hepatocellular carcinoma. Gastroenterology. 2008;135:1192-1199.
28. Loriot MA, Marcellin P, Walker F, et al. Persistence of hepatitis B virus DNA in serum and liver from patients with chronic hepatitis B after loss of HBsAg. J Hepatol. 1997;27:251-258.
29. Arase Y, Ikeda K, Suzuki F, et al. Long-term outcome after hepatitis B surface antigen seroclearance in patients with chronic hepatitis B. Am J Med. 2006;119:71.e9-71.e16.
30. Arase Y, Suzuki F, Suzuki Y, et al. Long-term presence of HBV in the sera of chronic hepatitis B patients with HBsAg seroclearance. Intervirology. 2007;50:161-165.
31. Chu CM, Liaw YF. Prevalence of and risk factor for hepatitis B viremia after spontaneous hepatitis B surface antigen seroclearance in hepatitis B carriers. Clin Infect Dis. 2012;54:88-90.
32. Wong GL, Wong VW, Choi PC, et al. Metabolic syndrome increases the risk of liver cirrhosis in chronic hepatitis B. Gut. 2009;58:111-117.
33. Yu MW, Shih WL, Lin CL, et al. Body-mass index and progression of hepatitis B: a population-based cohort study in men. J Clin Oncol. 2008;26:5576-5582.
34. Kumar M, Sarin SK, Hissar S, et al. Virologic and histogic features of chronic hepatitis B virus-infected asymptomatic patients with persistently normal ALT. Gastroenterology. 2008;134:1376-1384.